Urology eLearning Workshop, A guide to NMIBC - Module 1 – Aetiology and Diagnosis of NMIBC

This is the sixth module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you finish this module, you should be able to, Explain how you would prepare in advance, to avoid and manage an accidental spillage, Describe the steps for safe usage, to protect staff and patients, Describe the steps for safe disposal, Describe the steps for dealing with exposure or a spillage.

This is the second module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you finish this module, you should understand, How and why we came to use intravesical therapy for bladder cancer, How the current approach to treatment developed over time, in line with emerging evidence, The rationale behind two key treatments for non-muscle invasive bladder cancer (NMIBC), Mitomycin C (MMC) and bacillus Calmette-Guérin (BCG), The basic mode of action for BCG and MMC.

This is the third module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you finish this module, you should be able to describe the following for this condition, The role of bladder cancer guidelines in clinical practice, Basics of evidence-based guidelines development, Recommendations for NMIBC in the latest UK (NICE) guidelines on bladder cancer, How they compare to European (EAU, European Association of Urology) guidelines on NMIBC.

This is the fourth module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you finish this module, you should have an awareness of, The core competencies required for the administration of intravesical chemotherapy for bladder cancer, How to promote patient welfare, How intravesical chemotherapy is administered, Post-operatively, immediately after TURBT (trans-urethral resection of bladder tumour), and Later on in the outpatient department, as a continuing course of treatment, Safe handling and disposal of cytotoxic agents, Key stages of documentation, Your role in ensuring continuity of care.

This is the fifth module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you have completed this module, you should be able to, Outline key information that patients should receive about intravesical Mitomycin C (MMC) and intravesical Bacillus Calmette-Guérin, (BCG) for NMIBC, Describe the most common side effects of these two agents, Name some steps that can help patients manage side effects and complete their treatment, Describe the contraindications for MMC and BCG intravesical therapies, Describe precautions to consider for patients receiving these treatments.

This interactive case study aims to consolidate learning, following the 6 Urology NMIBC eLearning modules. It covers a full range of topics within non-muscle invasive bladder cancer. The case study is aimed at Urology nurses of all levels of experience, and is intended to refresh and further their learning within the therapy area.